Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
National Cancer Centre, Singapore
With
This study will enroll 100 patients randomized in a 1:1 allocation ratio (50 in each arm) to one of the two arms. * Study arm: SIRT-Y90 + 1200mg atezolizumab + 15mg/kg bevacizumab * Control arm: SIRT-Y90 + placebos (IV) The patients will be recruited from up to 15 sites from the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group (subjected to feasibility studies and ethics approval). Proposed sites are in Singapore, China, South Korea, and Taiwan.
Age
21–99
Sex
ALL
Healthy volunteers
Not accepted
